<DOC>
	<DOCNO>NCT02224820</DOCNO>
	<brief_summary>IdeS immunoglobulin g ( IgG ) cleave enzyme . It give patient donor specific antibody reduce antibody load thus enable kidney transplantation . IdeS antibody reduce efficacy safety study .</brief_summary>
	<brief_title>Phase II Study , Evaluation Safety Efficacy IdeS Chronic Kidney Disease</brief_title>
	<detailed_description>Study 13-HMedIdeS-02 ( EudraCT . 2013-005417-13 ) single centre , single arm , dose finding , Phase II study sensitize CKD patient assess safety , tolerability , pharmacokinetics ( PK ) efficacy HMED-IdeS without intent transplantation . However , patient remove transplant waitlist study . Included patient panel reactive antibody [ PRA ] &gt; 70 % ( n=7 ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Diagnosed chronic kidney disease dialysis identify antibody least two HLA antigen least one 3000 MFI measure SAB assay least two occasion . Prior malignancy within 2 year exclude adequately treat basal cell squamous cell skin cancer , cervical carcinoma situ prostate cancer Gleason &lt; 6 prostatespecific antigen ( PSA ) &lt; 10 ng/mL . Any positive result screen serum hepatitis B surface antigen , hepatitis C antibody human immunodeficiency virus ( HIV Clinical sign ongoing infectious disease . Severe condition require treatment close monitoring , e.g . cardiac failure &gt; New York Heart Association ( NYHA ) grade 3 , unstable coronary disease oxygen dependent chronic obstructive pulmonary disease ( COPD ) History clinically significant disease disorder , opinion investigator , may either put patient increase risk participation study , influence result patient 's ability participate study Hypogammaglobulinemia define value Ptotal IgG le 3 g/L History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class IdeS ( e. g streptokinase and/or staphylokinase ) Has receive another new chemical entity ( define compound approve marketing ) participate clinical study include drug treatment within 4 month first administration investigational product study . Patients consent screen dose previous study exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>transplantation</keyword>
	<keyword>sensitise patient</keyword>
	<keyword>HLA-antibodies</keyword>
</DOC>